Intrexon Corporation (NYSE:XON) : Traders are bullish on Intrexon Corporation (NYSE:XON) as it has outperformed the S&P 500 by a wide margin of 4.06% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.05%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.33% in the last 1 week, and is up 5.74% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -42.41% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $69.45 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $26.77 and the 200 Day Moving Average price is recorded at $30.06.
The stock has recorded a 20-day Moving Average of 6.84% and the 50-Day Moving Average is 0.47%.
Intrexon Corporation (NYSE:XON): stock turned positive on Friday. Though the stock opened at $25.89, the bulls momentum made the stock top out at $27.24 level for the day. The stock recorded a low of $25.84 and closed the trading day at $26.72, in the green by 3.21%. The total traded volume for the day was 1,353,978. The stock had closed at $25.89 in the previous days trading.
In an insider trading activity, Kirk Randal J, CEO of Intrexon Corp, executed a transaction worth $3,714,334 on December 11, 2015. A total of 124,475 shares were purchased at an average price of $29.84. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.